Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
600998.SS
BUYGet insider-trade alertsJointown Pharmaceutical Group Co., Ltd · Healthcare · China · $3.4B · Avg Vol: $23M/d
COMPANY DESCRIPTION
Jointown Pharmaceutical Group Co., Ltd is the largest non-state-owned pharmaceutical distributor in China, providing logistics and supply chain services to hospitals, pharmacies, and clinics. The company's competitive moat is built on its highly efficient, nationwide modern logistics network and its proprietary B2B e-commerce platform. It is a market leader in the third-party pharmaceutical logistics segment, characterized by high volume and low-cost operations.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 20.7B | 22.1B | 22.4B | 23.8B | 4.7% | 24.2B | 25.0B | 26.5B | 5.6% |
| EPS | 0.06 | 0.06 | 0.07 | 0.06 | 3.6% | 0.06 | — | — | — |
| Shares | 5.0B | 5.0B | 5.0B | 5.0B | +0.0% | 5.0B | — | — | — |
| Debt | 2.2B | 2.2B | 1.9B | 2.2B | -0.2% | 2.8B | — | — | — |
| Equity | 3.6B | 3.5B | 4.0B | 4.2B | 5.0% | — | — | — | — |
| Op CF | 587.1M | 699.2M | 454.0M | 506.7M | -4.8% | 551.6M | — | — | — |
| Inv CF | 219.1M | -200.5M | -234.4M | -24.7M | — | — | — | — | — |
| Fin CF | -721.8M | -329.5M | -368.2M | -366.3M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 600998.SS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| 600998.SS | Jointown Pharmaceutical Group Co., Ltd(you) | $3.4B | 80 | BUY |
| 0874.HK | Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited | $2.9B | 85 | STRONG BUY |
| 600056.SS | China Meheco Group Co., Ltd. | $1.9B | 80 | BUY |
| 600511.SS | China National Medicines Corporation Ltd. | $2.9B | 98 | STRONG BUY |
| 301015.SZ | Qingdao Baheal Medical INC. | $1.5B | 86 | STRONG BUY |
| 2607.HK | Shanghai Pharmaceuticals Holding Co., Ltd | $5.5B | 97 | STRONG BUY |
| 1099.HK | Sinopharm Group Co. Ltd. | $6.3B | 96 | STRONG BUY |
| 000028.SZ | China National Accord Medicines Corporation Ltd. | $1.7B | 96 | STRONG BUY |
| 600739.SS | Liaoning Cheng Da Co., Ltd. | $2.2B | 56 | HOLD |
| 603368.SS | Guangxi LiuYao Group Co., Ltd | $854M | 92 | STRONG BUY |
Peer medians: ROE 4.8% · P/E 26.5x · Gross margin 52.5%